IL12B and IL17 genes polymorphisms associated with differential susceptibility to juvenile idiopathic arthritis and juvenile-onset systemic lupus erythematosus in Chinese children.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
04 Aug 2023
04 Aug 2023
Historique:
medline:
7
8
2023
pubmed:
6
8
2023
entrez:
6
8
2023
Statut:
ppublish
Résumé
Genetic factors play a crucial role in the immune response of juvenile idiopathic arthritis (JIA) and juvenile-onset systemic lupus erythematosus (JSLE). This study aimed to investigate the association of IL12B (rs3212227, rs6887695) and IL17 (rs2275913, rs763780) gene polymorphisms with the susceptibility of JIA and JSLE in Chinese children. A total of 303 healthy controls and 304 patients including 160 JIA and 144 patients were analyzed, and the genetic polymorphisms were genotyped by using a Sequenom MassArray system. There was a significant association between the IL12B rs3212227 genotype and the increased risk of JSLE (P = .01). For rs6887695, the minor allele C was significantly associated with the increased risk of JIA (odds ratio = 1.48, 95% confidence interval [CI] = 1.12-1.95, P = .005). Moreover, rs6887695 genotype was significantly associated with both JIA and JSLE susceptibility (P < .05). Besides, IL12B haplotype GC significantly associated with the increased risk of JIA (P = .016). However, no significant difference was found between the IL17 (rs2275913, rs763780) gene polymorphisms and JIA or JSLE susceptibility (P > .05). And similar genotype distributions of IL12B and IL17 polymorphisms were found between the patients with nephritis and without nephritis in JSLE (P > .05). Our results indicated that IL12B polymorphisms was associated with an increased risk for the development of JIA and JSLE in Chinese children, highlighting the involvement of inflammation in the pathogenesis of JIA and JSLE. Moreover, there was a risk haplotype in IL12B which could increase the risk of JIA.
Identifiants
pubmed: 37543802
doi: 10.1097/MD.0000000000034477
pii: 00005792-202308040-00045
pmc: PMC10403002
doi:
Substances chimiques
IL12B protein, human
0
Interleukin-12 Subunit p40
0
IL17A protein, human
0
Interleukin-17
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e34477Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Acta Reumatol Port. 2016 Apr-Jun;41(2):151-7
pubmed: 27606475
Immunol Invest. 2021 Aug;50(6):685-699
pubmed: 32605468
Inflamm Res. 2013 Aug;62(8):743-50
pubmed: 23652560
Scand J Immunol. 2017 Feb;85(2):147-154
pubmed: 27896842
Curr Opin Rheumatol. 2019 Mar;31(2):185-192
pubmed: 30672908
BMC Musculoskelet Disord. 2016 May 11;17:208
pubmed: 27169372
Rheumatol Int. 2021 Dec;41(12):2205-2213
pubmed: 34554306
Cytokine Growth Factor Rev. 2014 Aug;25(4):415-21
pubmed: 25130295
Rheumatol Int. 2013 Jul;33(7):1785-90
pubmed: 23297015
Methods Mol Biol. 2014;1134:1-16
pubmed: 24497350
Lancet. 2011 Jun 18;377(9783):2138-49
pubmed: 21684384
PLoS One. 2012;7(8):e43661
pubmed: 22937072
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
J Endocrinol Invest. 2010 Jul-Aug;33(7):451-4
pubmed: 20061784
Nat Rev Immunol. 2003 Feb;3(2):133-46
pubmed: 12563297
Cytokine. 2015 Apr;72(2):146-53
pubmed: 25647269
Egypt J Immunol. 2020 Jan;27(1):19-28
pubmed: 33180384
Medicine (Baltimore). 2019 Mar;98(12):e14944
pubmed: 30896662
Sci Rep. 2016 Apr 06;6:24095
pubmed: 27048905
Rheumatol Int. 2019 Jan;39(1):111-119
pubmed: 30443744
Clin Immunol. 2019 Dec;209:108274
pubmed: 31678365
J Pers Med. 2021 Jun 07;11(6):
pubmed: 34200121
Nat Rev Rheumatol. 2010 Sep;6(9):538-46
pubmed: 20683438
Immunol Invest. 2021 May;50(4):416-426
pubmed: 32543936
Gene. 2020 Aug 30;753:144814
pubmed: 32464244
Front Immunol. 2021 Jul 05;12:653611
pubmed: 34290697
Scand J Immunol. 2010 Aug;72(2):134-41
pubmed: 20618772
Genes Immun. 2000 Dec;1(8):515-20
pubmed: 11197695
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Immunity. 2004 Oct;21(4):467-76
pubmed: 15485625
Scand J Immunol. 2016 Jul;84(1):49-60
pubmed: 27059274
Bioinformatics. 2005 Jan 15;21(2):263-5
pubmed: 15297300
PLoS One. 2012;7(9):e43428
pubmed: 22984424
Best Pract Res Clin Rheumatol. 2013 Jun;27(3):351-62
pubmed: 24238692
Immunol Invest. 2021 Nov;50(8):987-1006
pubmed: 33390082
Mod Rheumatol. 2016 Sep;26(5):749-56
pubmed: 26915668
Genes Immun. 2012 Apr;13(3):282-7
pubmed: 22130325
Mediators Inflamm. 2021 Oct 27;2021:3125922
pubmed: 34744511
Gene. 2019 Jun 20;702:107-113
pubmed: 30898714
Immunol Invest. 2020 Feb;49(1-2):1-14
pubmed: 31161840
Rheum Dis Clin North Am. 2017 Aug;43(3):435-448
pubmed: 28711144
Gene. 2013 Jan 10;512(2):477-81
pubmed: 23137633
Arch Immunol Ther Exp (Warsz). 2017 Dec;65(6):537-543
pubmed: 28547498
Rheumatol Int. 2012 Jan;32(1):53-9
pubmed: 20658240
Cell. 1996 May 3;85(3):311-8
pubmed: 8616887